Mitsubishi Tanabe Pharma Corporation revised earnings guidance for the full fiscal year ending March 31, 2019. For the period, the company expects revenue of JPY 424,500 million against JPY 435,000 previous forecast. Operating profit will be JPY 50,000 million against JPY 67,000 previous forecast. Core operating profit will be JPY 55,500 million against JPY 70,000 previous forecast. Profit for the period will be JPY 32,000 million against JPY 44,500 previous forecast. Basic earnings per share will be JPY 65.98 against JPY 83.81 previous forecast.